EVERSANA and Waltz Health have merged to create a new healthcare platform, with the goal of redefining pharmaceutical commercialization and patient access. The merger combines EVERSANA’s global commercialization services with Waltz Health’s software-powered drug-price marketplaces and direct-to-payer model, enabling a modern approach to drug access and value in the U.S. healthcare system.
EVERSANA operates in the pharma commercialization space, providing end-to-end services to the top 50 pharma and biotech companies. Waltz Health contributes digital technology solutions, including AI-powered prescription routing and affordability tools, connecting patients, payers and pharmaceutical companies to streamline drug access and lower costs.
The combined company will address drug pricing and patient accessibility challenges by integrating Waltz’s payer connectivity and drug affordability solutions into EVERSANA’s services. Its new model will focus on improving access to high-cost therapies, particularly specialty medications, and it is poised to drive significant cost savings and enhance patient outcomes across the healthcare system.
